lumo-20230628

0001126234-23-000081.txt : 20230628 0001126234-23-000081.hdr.sgml : 20230628 20230628162608 ACCESSION NUMBER: 0001126234-23-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230628 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230628 DATE AS OF CHANGE: 20230628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LUMOS PHARMA, INC. CENTRAL INDEX KEY: 0001126234 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421491350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35342 FILM NUMBER: 231052546 BUSINESS ADDRESS: STREET 1: 4200 MARATHON BLVD. STREET 2: SUITE 200 CITY: AUSTIN STATE: TX ZIP: 78756 BUSINESS PHONE: 512-215-2630 MAIL ADDRESS: STREET 1: 4200 MARATHON BLVD. STREET 2: SUITE 200 CITY: AUSTIN STATE: TX ZIP: 78756 FORMER COMPANY: FORMER CONFORMED NAME: NEWLINK GENETICS CORP DATE OF NAME CHANGE: 20001012 8-K 1 lumo-20230628.htm 8-K lumo-20230628

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

June 28, 2023

Date of Report (date of earliest event reported)

LUMOS PHARMA, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-35342	42-1491350
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

4200 Marathon Blvd., Suite 200

Austin, Texas 78756

(Address of Principal Executive Offices)

(512) 215-2630

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	LUMO	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On June 28, 2023, Lumos Pharma, Inc. issued a press release titled "Lumos Pharma Announces Departure of Chief Medical Officer."

A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Press Release, dated June 28, 2023, entitled "Lumos Pharma Announces Departure of Chief Me dical Officer."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 28, 2023


			LUMOS PHARMA, INC., a Delaware corporation


By:			/s/ Richard J. Hawkins
			Richard J. Hawkins
Its:			Chief Executive Officer

EX-99.1 2 lumo-20230628x8kxex991.htm EX-99.1 Document

Lumos Pharma Announces Departure of Chief Medical Officer

AUSTIN, TX, June 28, 2023 – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29th. Dr. Pisit “Duke” Pitukcheewanont, Lumos Pharma’s Senior Vice President, Global Clinical Development and Medical Affairs, along with other members of our clinical team, will oversee all clinical activities and related functions until a CMO search is complete.

“We thank David for his many contributions to Lumos Pharma and know he will continue to advance the field of endocrinology in his work with Stanford University,” said Rick Hawkins, Chairman and Chief Executive Officer of Lumos Pharma. “Dr. Duke Pitukcheewanont, a pediatric endocrinologist with over 25 years’ experience and President of the Human Growth Foundation for 12 years, has been instrumental in the recruitment and conduct of our ongoing clinical trials. We are confident that Dr. Pitukcheewanont, along with our experienced clinical team, will continue to advance our programs effectively while we conduct a search for a permanent CMO replacement to execute the rollout of our planned Phase 3 development program.”

About Pediatric Growth Hormone Deficiency and LUM-201

Pediatric Growth Hormone (GH) Deficiency is the consequence of inadequate secretion of growth hormone from the pituitary gland in children resulting in low GH in the body, insufficient production of downstream signaling molecules required for growth, and the subsequent lack of growth. LUM-201, also known as ibutamoren, is an orally administered investigational small molecule that promotes the secretion of GH from the pituitary gland and represents an opportunity for appropriately selected patients to avoid the daily or weekly injections involved with current or forthcoming therapies. LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion, which mimics the natural pattern of GH secretion.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in several Phase 2 clinical trials for the treatment of idiopathic Pediatric Growth Hormone Deficiency (iPGHD): the dose-finding OraGrowtH210 Trial; the PK/PD mechanistic OraGrowtH212 Trial; and a switch trial, the OraGrowtH213 Trial. If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

###

Investor & Media Contact:

Lisa Miller

Lumos Pharma Investor Relations

512-792-5454

ir@lumos-pharma.com

EX-101.SCH 3 lumo-20230628.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 lumo-20230628_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 lumo-20230628_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Address Line Two Entity Address, Address Line Two Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Address Type [Domain] Address Type [Domain] City Area Code City Area Code Entities [Table] Entities [Table] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Entity Information [Line Items] Entity Information [Line Items] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] Cover [Abstract] Document Type Document Type Entity Address, State or Province Entity Address, State or Province Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 lumo-20230628_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0a.jpg begin 644 image_0a.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information Document	Jun. 28, 2023
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Jun. 28, 2023
Entity Registrant Name	LUMOS PHARMA, INC.
Entity Central Index Key	0001126234
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-35342
Entity Tax Identification Number	42-1491350
City Area Code	512
Local Phone Number	215-2630
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	LUMO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Address, Address Line One	4200
Entity Address, Postal Zip Code	78756
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Address Line Two	Marathon Blvd., Suite 200

XML 9 lumo-20230628_htm.xml IDEA: XBRL DOCUMENT 0001126234 2023-06-28 2023-06-28 0001126234 false 8-K 2023-06-28 LUMOS PHARMA, INC. DE 001-35342 42-1491350 4200 Marathon Blvd., Suite 200 Austin TX 78756 512 215-2630 false false false false Common Stock LUMO NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://lumospharma.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports lumo-20230628.htm lumo-20230628.xsd lumo-20230628_def.xml lumo-20230628_lab.xml lumo-20230628_pre.xml lumo-20230628x8kxex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lumo-20230628.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "lumo-20230628_def.xml" ] }, "inline": { "local": [ "lumo-20230628.htm" ] }, "labelLink": { "local": [ "lumo-20230628_lab.xml" ] }, "presentationLink": { "local": [ "lumo-20230628_pre.xml" ] }, "schema": { "local": [ "lumo-20230628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 28, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lumo", "nsuri": "http://lumospharma.com/20230628", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lumo-20230628.htm", "contextRef": "ica056068d0d94f008773433aa11181bd_D20230628-20230628", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information Document", "menuCat": "Cover", "order": "1", "role": "http://lumospharma.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lumo-20230628.htm", "contextRef": "ica056068d0d94f008773433aa11181bd_D20230628-20230628", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://lumospharma.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001126234-23-000081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001126234-23-000081-xbrl.zip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end